Trial Profile
A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients With Relapsing Neuromyelitis Optica Spectrum Disorder
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Neuromyelitis optica
- Focus Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
- 27 Oct 2023 This trial has been completed in Germany (global end date: 2023-07-31), according to European Clinical Trials Database.
- 25 Jul 2023 Planned primary completion date changed from 1 Jul 2023 to 16 Aug 2023.
- 25 Jul 2023 Status changed from recruiting to active, no longer recruiting.